Bristol Myers Squibb Company
NEWS
The FDA approval was based on data from the Phase III Explorer-HCM trial that showed Bristol Myers Squibb’s Camzyos could decrease the heart’s contractility.
Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70% of its workforce. This comes only weeks after BMS abandoned its clinical collaboration program with Nektar.
Triebel holds the distinction of having discovered LAG-3 in 1990. Today, the company he founded is leveraging the handy molecule against cancer and autoimmune disease.
Bristol Myers Squibb will hear from the FDA on April 28 about Mavacamten, while Supernus, Axsome, Coherus, Hutchmed and Incyte also await the fate of their respective drug candidates.
Octant announced an $80 million Series B financing round, a Deep Mutual Scanning (DMS) biopharma partnership with Bristol Myers Squibb and key appointments to its leadership.
Bristol Myers Squibb and Nektar Therapeutics ended their global clinical program for potential bladder cancer and renal cell carcinoma treatment.
Be Biopharma closed a massive $130M financing to further its proprietary autologous and allogeneic BeCM platform and discover therapies for cancer, rare diseases and more.
Hundreds of presentations on oncology research are highlighted at the AACR Annual Meeting, which is running from April 7 to 13 in New Orleans.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
JOBS
IN THE PRESS